Monday, November 19, 2012

• NJ drug company execs charged with insider tradingAP (Mon, Nov 19)
• 2 Biopharmaceutical Stocks with Strong Net Cashat Motley Fool (Mon, Nov 19)
• Celgene's Lazorchak, Five Others, Charged With Insider TradingBloomberg (Mon, Nov 19)

Saturday, November 17, 2012

• This Week in Biotech: Part 2at Motley Fool (Sat, Nov 17)

Friday, November 16, 2012

• Abraxane Cancer Trials Help Justify Celgene Buyoutat Investor's Business Daily (Fri, Nov 16)
• 3 Horrendous Health-Care Stocks This Weekat Motley Fool (Fri, Nov 16)
• What Is So Exciting About MEI Pharma?at Seeking Alpha (Fri, Nov 16)
• Is Threshold on the Threshold?at Motley Fool (Fri, Nov 16)
• S&P 500 Stocks Biggest Weekly Changes in Target Priceat Bloomberg (Fri, Nov 16)
• The Zacks Analyst Blog Highlights: Starbucks Corporation, Tevana Holdings, Inc., Celgene Corporation, Amgen Inc. and Pfizer Inc.Zacks (Fri, Nov 16)

Thursday, November 15, 2012

• 3 Big Biotech Trial Resultsat Motley Fool (Thu, Nov 15)
• Celgene's Apremilast EncouragesZacks (Thu, Nov 15)

Wednesday, November 14, 2012

• It's Time To Buy Back Celgene On Abraxaneat Seeking Alpha (Wed, Nov 14)

Tuesday, November 13, 2012

• Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic ArthritisBusiness Wire (Tue, Nov 13)
• Cramer: Sell Choice Hotels and Buy Celgene, Ascena Group and This Mover Todayat Wall St. Cheat Sheet (Tue, Nov 13)
• Celgene Hits the Mark With Abraxaneat Motley Fool (Tue, Nov 13)
• Stock Downgrades: Molycorp Can No Longer Be Mollycoddledat Minyanville (Tue, Nov 13)
• Why Clovis Oncology's Shares Were Decimatedat Motley Fool (Tue, Nov 13)
• Cramer's Mad Money - Will There Be A Bull In The China Shop In 2013? (11/12/12)at Seeking Alpha (Tue, Nov 13)
• Clovis Oncology: This Treatment is Out of Reachat Wall St. Cheat Sheet (Tue, Nov 13)

Monday, November 12, 2012

• Cramer's 'Mad Money' Recap: Don't Let Politics Get You Downat TheStreet (Mon, Nov 12)
• Gilead Sciences And Celgene Liven Up Biotech ETFsat Investor's Business Daily (Mon, Nov 12)
• 3 Winning Trades Likely Missed Due to 'Fiscal Cliff'at CNBC (Mon, Nov 12)
• Movers roundup: Celgene, Clovis OncologyAP (Mon, Nov 12)
• 2 Reasons You Should Love This Biotech's Good Newsat Motley Fool (Mon, Nov 12)

Add CELG News to My Yahoo!